Posters presented at the American Academy of Dermatology 2024 Annual Meeting identified significant health disparities among patients living in rural areas and those with skin of color (SOC).
This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
Two posters presented at the American Academy of Dermatology 2024 Annual Meeting evaluated urban-rural differences in skin cancer survival, as well as the impact of having skin of color (SOC). These findings add to the understanding of how health disparities related to rural living and SOC negatively impact survival outcomes.
The first poster aimed to identify differences in demographic characteristics and the treatment of patients with sebaceous carcinoma, a rare and aggressive form of skin cancer with metastatic potential.1 Additionally, the researchers analyzed survival outcomes for patients with sebaceous carcinoma who live in urban vs rural locations in the US.
The researchers evaluated differences in clinical, sociodemographic, disease, facility, and travel characteristics using data from the National Cancer Databases from 2016 to 2020. Survival differences were evaluated using Cox proportional hazards models and Kaplan-Meier curves.
A total of 1871 patients were identified, of whom 40.03% were women and 59.97% were men. Of these patients, 1797 met inclusion criteria, had been diagnosed with sebaceous carcinoma, and were included in the analysis. Most patients identified as White (89.95%) and non-Hispanic (90.97%).
Patients with sebaceous carcinoma living in rural areas traveled more than twice as far for treatment (55.1 miles) compared with urban residents (26.6 miles). Additionally, patients living in rural areas were more likely from lower-income communities (P < .001) and had lower educational attainment (P < .05). Furthermore, while most patients had been treated with surgery alone (89.04%), rural residents were more likely to undergo major amputation (2.36%) compared with urban residents (0.54%; P < .01).
Moreover, rural living was associated with increased risk of death (HR, 1.49; 95% CI, 1.11-1.98), while survival probabilities for rural residents were worse at 3 years (77.1% vs 85.2%; P < .01) and 5 years (62.2% vs 71.4%; P < .01) compared with urban residents.
A second poster aimed to examine the association between urban-rural status and skin cancer prevalence across social determinants of health (SDOH): sex, age, race, insurance status, number of personal health care providers (PHCPs), and income among those living in Florida.2
The researchers conducted a cross-sectional study using data from the Behavior Risk Factor Surveillance Survey 2018-2020. Positive skin cancer history was determined using a self-reported survey, and urban-rural status was identified according to the National Center for Health Statistics‘ definitions.
A total of 35,742 individuals were identified; 17.1% of rural and 14.9% of urban respondents reported having a history of skin cancer.
No significant differences were found between the prevalence of skin cancer and urban-rural status among non-Hispanic White individuals. However, non-Hispanic Black individuals living in rural areas reported a higher incidence of skin cancer history (1.6%) compared with non-Hispanic Black individuals living in urban areas (0.6%; P < .001). Similarly, this discrepancy between rural-urban status and skin cancer was noted among Asian (P < .001), Hispanic (P < .0001), and other non-Hispanic (P < .05) individuals.
Furthermore, increased rural skin cancer rates were observed across sex, income, insurance status, and PHCP.
These findings highlight an increased history of skin cancer among rural SOC populations, suggesting a need for further research on these disparities among communities of color.
References
1. Chang R, Brunsgaard E, Reid D, et al. Rural-urban survival differences in sebaceous carcinoma: a national cancer database analysis. Poster presented at: American Academy of Dermatology 2024 Annual Meeting; March 8-12, 2024. San Diego, CA. Poster 49792. https://eposters.aad.org/abstracts/49792
2. Lin R, Lee J, Maderal A, et al. The urban-rural impact on skin cancer for skin of color. Poster presented at: American Academy of Dermatology 2024 Annual Meeting; March 8-12, 2024. San Diego, CA. Poster 51459. https://eposters.aad.org/abstracts/51459
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More